Melanotan II Dosage, Protocol, and Reconstitution Guide

Melanotan II / MT2

Melanotan II (MT2) is a synthetic peptide related to alpha-MSH, a natural hormone involved in skin pigmentation. It stimulates melanocortin receptors and is commonly discussed in research and peptide communities for tanning, pigmentation, and sometimes sexual-response effects.

How It Works

Melanocortin Receptor Activation → Melanin Production ↑ → Skin Pigmentation ↑

Melanotan II activates melanocortin receptors involved in pigmentation and other body functions. Its tanning effect mainly comes from stimulating melanin production in the skin. Because it also affects other melanocortin receptors, it can cause side effects such as nausea, flushing, appetite changes, yawning, and spontaneous erections.

MT2 Research Standard / Loading Protocol

Research context:
The loading and maintenance ranges below reflect commonly discussed peptide-community protocols rather than an FDA-approved treatment schedule. Human Melanotan II studies used study-specific, weight-based dosing rather than this exact fixed-dose progression.

10 mg vial + 3.0 mL BAC Water → 1 unit = 33 mcg → Gradual Loading Then Maintenance

Standard Setup

Vial10 mg

Water3.0 mL

Concentration3.33 mg/mL

Conversion1 unit = 33 mcg

Days 1–3

Intro

Dose100 mcg

Units3 units

Volume0.03 mL

Days 4–7

Build

Dose200 mcg

Units6 units

Volume0.06 mL

Week 2+

Standard Range

Dose250–500 mcg

Units8–15 units

Volume0.08–0.15 mL

Simple approach:
Start low to reduce early side effects, then build gradually. Most people use a short daily loading phase before dropping to maintenance use.

Advanced Research Protocol

Higher Community-Discussed Range

Higher Exposure

Dose500–1000 mcg

Important:
Higher doses are discussed in some peptide communities, but side effects such as nausea, flushing, fatigue, appetite changes, and pigment changes may increase as exposure rises. More is not necessarily better.

How to Use MT2 (Cycle, Timing & Injection)

Research FrequencyOnce daily during loading

Research Maintenance1–2x weekly

Research Cycle Length2–4 weeks loading, then maintenance

Injection TypeSubcutaneous

Best TimeOften evening

Best Time to Take

Evening use is commonly preferred because it may make early nausea or flushing easier to tolerate.

Some people use it before planned UV exposure, but starting low and keeping the schedule consistent usually matters more than exact timing.

Avoid rushing dose increases because side effects often rise faster than the tanning response.

Where to Inject

Subcutaneous injection is the standard route discussed.

Abdomen is the most common site.

Upper arm or thigh may also be used.

Rotate sites regularly to reduce irritation.

When to Use

During a short pigmentation loading phase

When UV response or tanning support is the main goal

During maintenance phases after target pigmentation is reached

With careful monitoring of freckles, moles, and dark spots

UV Exposure Context

Some users combine Melanotan II with UV exposure to increase tanning response.

Melanotan II does not make UV exposure risk-free and should not be treated as protection against sun damage.

Tanning beds and excessive UV exposure still increase skin-cancer and photoaging risk.

Pigment changes in freckles, moles, or new dark spots should be monitored closely.

Simple Strategy

Start Low

MT2 is usually best approached slowly because nausea, flushing, yawning, appetite changes, and pigment changes can show up early.

Goal-Based Use

Use it in phases: load until the desired response begins, then reduce to maintenance or stop rather than continuing aggressively.

Reconstitution & Dosing (10 mg Vial)

Reconstitution & Dosing

Vial10 mg

Water3.0 mL

Concentration3.33 mg/mL

Conversion1 unit = 33 mcg

Dose Reference

3 units = 100 mcg

6 units = 200 mcg

8 units = about 250 mcg

15 units = about 500 mcg

30 units = about 1,000 mcg

Reconstitution Steps

Draw 3.0 mL bacteriostatic water

Inject slowly down vial wall

Gently swirl, do not shake

Refrigerate immediately

Storage & Shelf Life

Storage & Shelf Life

Lyophilized (unmixed)

Refrigerated (2–8°C): ~12–24 months

Frozen (−20°C): up to ~2–3 years

Store sealed, dry, and protected from light

Reconstituted (mixed)

Refrigerated (2–8°C): about 30 days typical use window

Do not freeze after mixing

Protect from light and avoid repeated temperature changes

Best Practice

Handling

Keep the vial cold, minimize unnecessary handling, and use clean technique every time the vial is accessed.

Visual Check

If the solution becomes cloudy, discolored, or contains floating particles, it is safer not to continue using it.

Research Cycle Length & Time Between Cycles

Loading Phase → Maintenance or Stop → Reassess Skin + Side Effects

Community Framework

Loading Phase Often discussed as 2–4 weeks

Maintenance Often 1–2x weekly

Time Off Often 2–4 weeks

Established Clinical Cycle? No

Why reassess?
Pigmentation and side effects can build over time. Community protocols often include periods off so users can reassess skin changes, nausea, appetite effects, and whether further exposure is necessary. There is no clinically established required off-cycle.

Monitoring During Use

Skin pigmentation changes

Freckle or dark spot development

UV response

Tolerance to dose

Skin-change warning:
Melanotan II can darken existing freckles and moles and may cause new pigmented spots to appear. Case reports have described dysplastic nevi and melanomas appearing during or after Melanotan use, although a direct cause-and-effect relationship has not been proven. Any new, rapidly changing, irregular, or unusually dark mole should be evaluated by a medical professional.

What Human Studies Have Found

Early Human Tanning Research

A small Phase I study tested subcutaneous Melanotan II in healthy male volunteers.

The study found increased skin pigmentation after repeated dosing.

Common effects included nausea, fatigue, yawning/stretching, and spontaneous erections.

The study used weight-based dosing rather than a standard fixed microgram community protocol.

Sexual-Response Research

Melanotan II was also studied in men with psychogenic erectile dysfunction.

In a small controlled study, most participants developed clinically apparent erections after Melanotan II.

Nausea, yawning, stretching, and reduced appetite were commonly reported.

Important distinction:

Human research confirms that Melanotan II can affect pigmentation and sexual-response pathways, but the community loading schedules commonly used today are not the same as validated clinical dosing protocols.

Commonly Reported / Studied Effects

Increased skin pigmentation

Tanning response has been demonstrated in early human research

Sexual-response effects, including spontaneous erections, have been observed in human studies

Reduced appetite has also been reported

Potential Side Effects

Nausea, especially early or at higher doses

Facial flushing

Yawning, stretching, or fatigue

Reduced appetite

Spontaneous or prolonged erections

Darkening of freckles and existing moles

Development of new pigmented spots or nevi

Injection-site irritation

Rare reports of serious systemic reactions have occurred with unregulated products

Combination Considerations

Community Discussion

Melanotan II is sometimes discussed alongside general skin-support compounds such as GHK-Cu.

There are no clinically validated peptide-stacking protocols involving Melanotan II.

Adding more compounds does not reduce the need to monitor pigment changes, moles, and UV exposure.

Important Notes

Melanotan II has shown tanning activity in small human studies.

The loading and maintenance schedules commonly used today are community frameworks, not FDA-approved dosing protocols.

Nausea, flushing, appetite changes, yawning, and sexual-response effects can occur.

Existing freckles and moles may darken, and new pigmented spots may appear.

Published case reports describe dysplastic nevi and melanoma occurring during or after Melanotan use, although a direct causal relationship has not been proven.

Melanotan II does not protect against UV damage or make tanning beds safe.

Unregulated product purity and dosing accuracy are additional safety concerns.

Important Disclaimer

Melanotan II is an investigational peptide and is not FDA-approved for tanning, sexual enhancement, or other therapeutic use. Human studies exist, but commonly used community dosing protocols have not been established as approved treatment regimens. Unregulated products may also carry additional purity and safety risks. This content is for educational purposes only.

Research & References

Primary Research

• Hadley ME, Dorr RT. Melanocortin Peptide Therapeutics: Historical Milestones, Clinical Studies and Commercialization. Peptides. 2006.
• Wessells H, Gralnek D, Dorr R, Hruby VJ, Hadley ME, Levine N. Effect of an Alpha-Melanocyte Stimulating Hormone Analog on Penile Erection and Sexual Desire in Men with Organic Erectile Dysfunction. Urology. 2000.
• Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. Evaluation of Melanotan-II, a Superpotent Cyclic Melanotropic Peptide in a Pilot Phase-I Clinical Study. Life Sciences. 1996.
• Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. Potent and Prolonged Acting Cyclic Lactam Analogues of Alpha-Melanotropin: Design Based on Molecular Dynamics. Journal of Medicinal Chemistry. 1989.
• Abdel-Malek ZA, Scott MC, Furumura M, et al. The Melanocortin 1 Receptor Is the Principal Mediator of the Effects of Agouti Signaling Protein on Mammalian Melanocytes. Journal of Cell Science. 2001.

Research Note: Melanotan II dosing protocols in circulation come primarily from early-phase human pharmacology studies and non-prescription source practices rather than large standardized clinical trials; the compound has never received FDA approval.

Melanotan II Guide → Peptide Directory →